135-85-3

Basic information

• Product Name: 3,4-DIMETHOXYBENZYLHYDRAZINE
• Synonyms: 3,4-DIMETHOXYBENZYLHYDRAZINE;CHEMBRDG-BB 4015019;(3,4-dimethoxyphenyl)methylhydrazine;(3,4-dimethoxybenzyl)hydrazine(SALTDATA: FREE);Hydrazine, [(3,4-diMethoxyphenyl)Methyl]-
• CAS NO: 135-85-3
• Molecular Formula: C₉H₁₄N₂O₂
• Molecular Weight: 182.22
• EINECS: 266-257-8
• Mol File: 135-85-3.mol
• Article Data: 1

Chemical Properties

• Melting Point: 32-34 °C
• Boiling Point: 315.62°C (rough estimate)
• Flash Point: 157.3°C
• Appearance: /
• Density: 1.1450 (rough estimate)
• Vapor Pressure: 2.13E-09mmHg at 25°C
• Refractive Index: 1.4922 (estimate)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 7.07±0.70(Predicted)
• CAS DataBase Reference: 3,4-DIMETHOXYBENZYLHYDRAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DIMETHOXYBENZYLHYDRAZINE(135-85-3)
• EPA Substance Registry System: 3,4-DIMETHOXYBENZYLHYDRAZINE(135-85-3)

Safety Data

• Hazardous Substances Data: 135-85-3(Hazardous Substances Data)

Usage

General Description

3,4-Dimethoxybenzylhydrazine is a chemical compound with the molecular formula C10H14N2O2. It is a hydrazine derivative, specifically a compound in which a hydrazine group is linked to a benzene ring substituted with two methoxy groups at positions 3 and 4. 3,4-DIMETHOXYBENZYLHYDRAZINE is not well-studied in terms of its specific properties and uses, but hydrazines in general are known to have applications as pharmaceuticals, as intermediates in organic synthesis, and in the production of agrochemicals. The specific properties and applications of 3,4-dimethoxybenzylhydrazine would depend on its individual chemical reactivity and behavior.

InChI:InChI=1/C6H10N6/c7-4-10-5(8)12-6(11-4)9-3-1-2-3/h3H,1-2H2,(H5,7,8,9,10,11,12)

Upstream product

• 7306-46-9 4-chloromethyl-1,2-dimethoxy-benzene 

Downstream Products

• 3840-29-7 Benzaldehyd-veratrylhydrazon 

Relevant articles and documents

1-Substituted-3-amino-pyrazol-5-ones

Pharmaceutical compositions are prepared which comprise a diuretically effective amount, a saluretically effect amount or an antihypertensive amount of a compound of the formula SPC1 Or a pharmaceutically acceptable non-toxic salt thereof, wherein R is aryl which is either unsubstituted or substituted by A. 1, 2 or 3 identical or different substituents selected from the group consisting of halogen, alkyl of 1 to 8 carbon atoms, alkoxy of 1 to 8 carbon atoms, alkenoxy of 2 to 6 carbon atoms, cycloalkyl of 5 to 7 carbon atoms, trifluoromethyl, trifluoromethoxy and phenyl; B. 1 or 2 identical or different substituents selected from the group consisting of nitro, cyano, lower alkylamino of 1 to 4 carbon atoms, a carbonamido moiety of the formula EQU1 and a sulphonamido moiety of the formula EQU2 wherein R1 and R2 are each hydrogen or straight or branched chain alkyl of 1 to 4 carbon atoms, or R1 and R2 together with the nitrogen atom to which they are attached are linked together to form a 5-, 6- or 7-membered heterocyclic ring wherein the nitrogen atom is the only heteroatom or wherein oxygen is also present as a ring member; C. one substituent selected from the group consisting of dialkylamino of 1 to 4 carbon atoms in each alkyl moiety, nitro, cyano and SOn -alkyl of 1 to 4 carbon atoms, wherein n is 0, 1 or 2; D. one substituent selected from the group consisting of a moiety of the formula EQU3 wherein R1 and R2 are as above defined, nitro, cyano, a carbonamido moiety of the formula EQU4 wherein R1 and R2 are as above defined, a sulphonamide moiety of the formula EQU5 wherein R1 and R2 are as above defined, and SOn -alkyl of 1 to 4 carbon atoms, wherein n is 0, 1 or 2, and 1 or 2 substituents selected from the group consisting of alkyl of 1 to 8 carbon atoms, alkoxy of 1 to 6 carbon atoms, halogen and trifluoromethyl; E. an annellated-branched or unbranched, saturated or unsaturated, 5-, 6- or 7-membered isocyclic or heterocyclic ring having 1 or more heteroatoms selected from the group consisting of oxygen and sulphur and wherein said aryl moiety is either unsubstituted or chlorosubstituted; F. --O--(CH2)n' --N(alkyl)2, wherein the alkyl groups contain a total of 2 to 4 carbon atoms and n'is 2 or 3; or G. two different substituents selected from the group consisting of alkyl of 1 to 8 carbon atoms, phenyl, halogen, alkoxy of 1 to 8 carbon atoms, trifluoromethyl, trifluoromethoxy, lower alkylamino, nitro, cyano, SOn --alkyl of 1 to 4 carbon atoms, wherein n is 0, 1 or 2, a carbonamido moiety of the formula EQU6 and a sulphonamido moiety of the formula EQU7 wherein R3 and R4 are each hydrogen or alkyl of 1 to 4 carbon atoms; in combination with a pharmaceutically acceptable non-toxic inert diluent or carrier. Diuretic therapy, saluretic therapy and antihypertensive therapy is effected in humans and animals by administering an effective amount of the active ingredient as above defined.